Dyne Therapeutics, Inc. (DYN): Entry into a Material Definitive Agreement
Dyne Therapeutics, Inc. (DYN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 d112911dex11.htm EX-1.1 EX-1.1 Exhibit 1.1 UNDERWRITING AGREEMENT DYNE THERAPEUTICS, INC. 18,300,000 Shares of Common Stock, par value $0.0001 per share Underwriting Agreement July 21, 2026 Morgan Stanley & Co. LLC Jefferies LLC As Representatives of the several Underwri
How this was made
The 30-second read
Why it matters
The disclosed purchase price ($19.27) and share volume (18.3M plus up to 2.745M option) define the immediate dilution and financing overhang that traders typically price into the stock around offering mechanics.
Market read
This is a primary disclosure of a fixed-price equity offering size and per-share purchase price, which can drive near-term repricing due to dilution expectations.
What to watch
Net proceeds, intended use of funds, any concurrent share repurchase/hedging, and whether the option shares are likely to be exercised are not included in the excerpt, yet they materially affect valuation impact.
Background
The 8-K reports entry into a material definitive underwriting agreement tied to an automatic shelf registration (Form S-3) for common stock.
Ticker impact
Dyne Therapeutics entered an underwriting agreement to sell 18.3M shares, with an option for 2.745M more, at $19.27/share.
Likely near-term downside or volatility around offering execution, with magnitude depending on deal size vs. float and any concurrent demand/discount details not shown here.
An 8-K underwriting agreement is a primary-source capital raise disclosure. The text provides the share count and purchase price, but omits net proceeds, use of proceeds, and whether the offering is at-the-market vs. fixed-price, limiting precision on impact size.
Market effects
For biotech, equity offerings can signal funding needs and may affect sentiment toward small-cap development-stage peers.
Primarily US small-cap biotech sentiment; limited direct regional spillover beyond US-listed biotech capital markets.
Low global relevance unless the proceeds relate to a major international program or syndicate demand indicates broader risk appetite.
Counterpoint
If the offering is well-supported by underwriting demand and proceeds fund de-risking milestones, the dilution overhang may be temporary and could be absorbed quickly.
Key entities
- issuerDyne Therapeutics, Inc.
Subject of the 8-K, entering an underwriting agreement for a common stock offering.
- underwriterMorgan Stanley & Co. LLC
Representative underwriter named in the underwriting agreement.
- underwriterJefferies LLC
Representative underwriter named in the underwriting agreement.
